|
Type |
Symposium |
Area |
Current Trends in Organic Chemistry II: Organic Materials & Supramolecular Chemistry |
Room No. |
Room 304+305+306 |
Time |
FRI 09:00-: |
Code |
ORGN2-1 |
Subject |
Bispecific Antibody Conjugates for Cancer Immunotherapy |
Authors |
Chan Hyuk Kim Department of Life Science, KAIST, Korea |
Abstract |
Cancer immunotherapy has been drawing growing attention as a novel promising therapeutic modality for cancer. Unlike conventional chemo- or radiotherapy, immunotherapy treats cancer by unleashing the suppressed activity of the patient’s own immune system and harnessing its power to fight cancer, to achieve robust anti-tumor responses while minimizing collateral damages to normal tissues. Among several immunotherapeutic approaches, T cell-based immunotherapeutics such as bispecific antibodies and chimeric antigen receptor (CAR) T cells have generated unprecedented responses in clinics, and have become promising therapeutic modalities for the treatment of refractory cancers. In this talk, I will briefly discuss our recent efforts on developing novel approaches for T cell-based immunotherapeutic using novel bispecific antibody conjugates, in particular PSMA-targeting small molecule antibody conjugate and switchable CAR-T platform.
|
E-mail |
kimchanhyuk@kaist.ac.kr |
|